COMMUNIQUÉS West-GlobeNewswire

OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101)
21/01/2026
OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101) Nantes, le 21 janvier, 18 heures - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo : OSE) prend [...]
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
21/01/2026
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) Nantes, France, January 21, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today acknowledges [...]
AB Science obtient un brevet japonais pour l'utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu'en 2041
21/01/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE OBTIENT UN BREVET JAPONAIS POUR L'UTILISATION DU MASITINIB DANS LE TRAITEMENT DES FORMES PROGRESSIVES DE LA SCLÉROSE EN PLAQUES (SEP) JUSQU'EN 2041 IL S'AGIT DU PREMIER PAYS À OCTROYER LE [...]
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
21/01/2026
PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT MASITINIB HAS UNIQUE [...]
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
21/01/2026
The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery and Innovation TARRYTOWN, N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Society for Science (the Society) and [...]
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair
21/01/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has completed the acquisition of Integrity Orthopaedics, further strengthening its sports medicine shoulder repair business with [...]
Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”)
21/01/2026
ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society [...]
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
21/01/2026
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effects Nearly 8 in 10 adults and parents [...]
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
21/01/2026
The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026 LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical [...]
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
21/01/2026
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19 th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026 Oral [...]
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
21/01/2026
– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE [...]
NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts
21/01/2026
BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (“NewGen” or the “Company,” NASDAQ: NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and [...]
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
21/01/2026
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management [...]
LiveWorld Announces Human-Led, AI-Powered Strategy & 2026 Solutions Roadmap
21/01/2026
Company Unveils Seven AI Solutions for 2026, Built for The New Era of Healthcare Marketing CAMPBELL, Calif. and NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD). For nearly three decades, [...]
Manhattan Wellness Joins Lumina Therapy Alliance, Expanding the Nation’s Premier In-Person Mental Health Network
21/01/2026
Led by visionary founder Jennifer Teplin, Manhattan Wellness strengthens Lumina’s footprint for New York’s business community and signals rapid national expansion. NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lumina [...]
PerfectServe is Furthest in Vision and Highest in Execution in 2026 Gartner® Magic Quadrant™ for Clinical Communication and Collaboration
21/01/2026
Marks the company’s third consecutive placement as a Leader following recognition as highest in execution in 2023 and furthest in vision in 2024 KNOXVILLE, Tenn., Jan. 21, 2026 (GLOBE NEWSWIRE) -- PerfectServe ® , a [...]
Human Continuum Appoints Dr. Tsun “Sean” Law MD, MBA as its Chief Executive Officer to Lead the Research and Development Efforts Focused on Next-Generation Exosome Therapies and Over-the-Counter Exosome-based Products
21/01/2026
New York, N.Y., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”) , a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has [...]
ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial
21/01/2026
Marc Waldman brings over 35 years of commercial leadership experience in the medical device industry with a proven track record of driving top-line growth TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, [...]
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
21/01/2026
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate development of the elraglusib tablet in specific indications, including refractory melanoma and additional [...]

Pages